文献速递甲状腺疾病

儿童甲状腺髓样癌中新发现ALK融合

A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2019-01-01

本文报告一例10岁男孩患转移性甲状腺髓样癌,基线降钙素为6703 pg/mL,分子检测发现新型CCDC6-ALK融合;经克唑替尼及阿来替尼治疗后降钙素降至663 pg/mL,并持续应答。这是首例儿童ALK易位甲状腺髓样癌,提示识别ALK融合具有重要治疗意义。

要点

  • 儿童转移性甲状腺髓样癌中可存在CCDC6-ALK融合。
  • 该融合对ALK抑制剂具有显著临床敏感性。
  • ALK融合甲状腺髓样癌患者应考虑ALK靶向治疗。

核心结论

  • 新型CCDC6-ALK融合在一例儿童转移性甲状腺髓样癌中被发现,并对ALK抑制剂表现出显著临床敏感性。

研究设计与样本

  • 单例病例报告:10岁男孩,转移性甲状腺髓样癌,伴肺、淋巴结及肾上腺转移。

主要发现

  • 基线降钙素为6703 pg/mL,分子检测发现新型CCDC6-ALK融合。
  • ALK抑制治疗6天后降钙素降至663 pg/mL,患者持续使用阿来替尼并维持应答。

关键数值与推荐

  • ALK抑制治疗6天后降钙素从6703 pg/mL降至663 pg/mL。

临床怎么用

  • 对甲状腺髓样癌患者,尤其儿童病例,应考虑检测ALK融合以指导靶向治疗。

局限性

  • 本文为单例病例报告,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Medullary thyroid carcinoma (MTC) is most commonly associated with RET gene mutations. ALK fusions have rarely been described, although not previously in pediatrics and not previously partnered with CCDC6 in MTC or any other cancer. A 10-year-old boy with progressive stridor was found to have metastatic MTC, including lung, lymph node, and adrenal metastases. Baseline calcitonin was 6703 pg/mL. While molecular testing was pending, he was treated empirically with the investigational selective RET inhibitor, LOXO-292, without improvement. Molecular testing revealed a novel CCDC6-ALK fusion. His therapy was changed to crizotinib and then to alectinib for improved tolerability. Calcitonin decreased to 663 pg/mL after 6 days of ALK inhibition. He remains on alectinib with ongoing response. A novel CCDC6-ALK fusion has now been implicated in a pediatric case of metastatic MTC. This fusion has profound clinical sensitivity to ALK inhibitors. This report expands the spectrum of ALK fusions seen in MTC, including the first pediatric case of ALK translocated MTC. This novel fusion with CCDC6 has not previously been reported in other human cancers. Given the dramatic response to ALK inhibition in this case, identifying patients with ALK fusion MTC has important therapeutic implications.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Hillier K, Hughes A, Shamberger RC, et al. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019. PMID: 31650892. doi:10.1089/thy.2019.0041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。